Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...
The US Food and Drug Administration (:FDA) recently granted approval to Amgen’s (AMGN) Prolia (denosumab) for an additional indication. Prolia can now be used as a treatment for increasing bone mass ...
Common side effects of Prolia include bone and muscle pain, high cholesterol, and urinary tract infections. Prolia can also cause serious side effects such as fractures and severe infections, though ...
As people age, the risk of fracturing a bone – whether it’s a hip, a wrist, vertebrae, an ankle or toe, climbs steadily. For women and men who live after a cancer diagnosis, the risk of breaking bone ...
The US Food and Drug Administration (FDA) issued an alert today that cited preliminary evidence for a "substantial risk" for severe and symptomatic hypocalcemia and serious outcomes related to ...
Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...
Amgen notched up data for a new Prolia use that could amp up the blockbuster-in-the-making. In a late-stage trial, Prolia beat Allergan’s Actonel at building bone density in the hip and spine in ...
After being on the market for 14 years, the FDA has added a boxed warning to Amgen's osteoporosis drug Prolia for those who also have advanced chronic kidney disease. Use of Amgen’s osteoporosis drug ...
US regulators have approved a new indication for Amgen’s Prolia, allowing its use to treat glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture. US regulators have ...
Amgen has deployed “500 to 1,000” reps in support of Prolia, a biologic osteoporosis treatment that received FDA approval June 1. Sales reps “across [Amgen’s] bone health, inflammation and hospital ...
GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial for SPD8, a Denosumab biosimilar co-developed with Mitsubishi Gas Chemical, has successfully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results